Vaccine News and Research

Latest Vaccine News and Research

Emergent BioSolutions receives early termination grant to acquire Trubion

Emergent BioSolutions Inc. announced today that the U.S. Department of Justice and Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act"), as amended, with respect to the planned acquisition of Trubion Pharmaceuticals, Inc. by Emergent BioSolutions announced on August 12, 2010.

9 Sep 2010

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic

Emergent BioSolutions Inc. announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject. Emergent's fully human monoclonal antibody product candidate is being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.

8 Sep 2010

AVAC welcomes new Global HIV Vaccine Enterprise Scientific Strategic Plan

AVAC welcomes the new Global HIV Vaccine Enterprise Scientific Strategic Plan, released today, as a critical document that the field must implement as part of ongoing efforts to improve coordination, efficiency and transparency to quickly capitalize on recent advances in AIDS vaccine research.

8 Sep 2010

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. today announced that treatment with its lead compound, Homspera, in combination with a DNA vaccine utilizing Scancell's ImmunoBody technology significantly improved the immune response of the vaccine in an animal model.

8 Sep 2010

Risks of 'imported' measles

An outbreak of measles at an international youth soccer event illustrates the risks of with "imported" measles, according to a study in the September issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

8 Sep 2010

New vaccines fact sheet released by Research!America

Research!America is highlighting the vital importance of vaccines with a new fact sheet in its Investment in Research Saves Lives and Money series. CDC recently reported that routine vaccination rates are increasing among teens aged 13-17, but for many diseases the vaccination rates are far below the CDC's recommended 90% mark. With kids heading back to school and flu season fast approaching, now is a good time to remind readers of the importance of vaccines and disease prevention.

8 Sep 2010

Personalized reminders effective in encouraging seniors to get annual flu shots

Personalized post cards or phone calls can be effective in encouraging more seniors to get their annual flu shots, according to a new review of evidence. Professional facilitators are also successful at urging providers to perform a suite of preventive services, including flu shots for seniors.

8 Sep 2010

K-State University receives patent for procedures to source stem cells from umbilical cord

Kansas State University has been a issued a patent for a plentiful and noncontroversial source of stem cells from a substance in the umbilical cord.

8 Sep 2010

Fluctuation in PCV-7 vaccine dosing time increases pneumococcal serotype 19A strains: Study

Infants who received heptavalent pneumococcal conjugate vaccination (PCV-7) at 2, 4, and 11 months were more likely than unvaccinated controls to have nasopharyngeal (in the nasal passages and upper part of the throat behind the nose) acquisition of pneumococcal serotype 19A, a leading cause of respiratory pneumococcal disease, according to a study in the September 8 issue of JAMA.

8 Sep 2010

CDC ramps up production of new three-in-one flu vaccine

Health officials say that there will be plenty of flu vaccine available this year, now that the H1N1 pandemic has ended, The Washington Post reports. "The World Health Organization declared an end to the pandemic last month, based on indications that the H1N1 flu was transitioning to a more seasonal virus. Unlike last year, when there was one vaccine for H1N1 flu and another for seasonal flu, this year's vaccine is a 'three-in-one' that includes protection against H1N1 as well as two other strains."

8 Sep 2010

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.

7 Sep 2010

VOA News examines U.S. Global Health Initiative

VOA News examines President Barack Obama's $63 billion Global Health Initiative (GHI), noting the initiative's emphasis on cost-effective strategies to improve child- and maternal-health as well as programs to fight HIV/AIDS, tuberculosis (TB) and malaria. The article includes recent comments by Secretary of State Hillary Rodham Clinton on the role the GHI will play in strengthening health systems and the administration's on-going commitment to global HIV/AIDS programs.

4 Sep 2010

AVAC calls for economic and political support for CAPRISA 004 microbicide trial's critical follow-up studies

AVAC today issues a call to action to donors, policy-makers, researchers and advocates to ensure that critical follow-up studies to the landmark CAPRISA 004 microbicide trial receive the economic and political support needed to move forward as quickly as possible. The call comes as a group of microbicide and public health experts have agreed upon a plan for further studies, which are expected to cost $100 million over three years, of which only $58 million has been committed.

4 Sep 2010

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.

3 Sep 2010

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

Celldex Therapeutics, Inc. announced today it will regain full worldwide rights to develop and commercialize rindopepimut (CDX-110), effective November 1, 2010.

3 Sep 2010

Regional Director of WHO Africa warns of impact global financial situation will have on health systems, MDGs

Regional Director of WHO for Africa Luis Sambo discussed during the 60th session of the Africa Committee of the WHO how the global economic situation could impact funding for health programs in Africa and the ability for countries to reach U.N. Millennium Development Goal targets, PANA/Afrique en ligne reports.

3 Sep 2010

Research on immune system can develop new therapy for inflammation, tumors

In two closely related studies, two teams of Scripps Research Institute scientists have discovered the underlying mechanisms that activate a type of immune cell in the skin and other organs. The findings may lead to the development of new therapies to treat inflammation, wounds, asthma, and malignant tumors.

3 Sep 2010

BARDA awards contract to develop treatment for ionizing radiation exposure

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) today awarded a $153 million contract to Cellerant Therapeutics, Inc. of San Carlos, Calif., to continue developing a new way to treat an illness caused by exposure to high levels of ionizing radiation which can damage the body's cells - the type of radiation that would come from a nuclear blast.

3 Sep 2010

Researchers identify two proteins in cellular response to mechanical stimulation

Scripps Research Institute scientists have identified two proteins with potential to be important targets for research into a wide range of health problems, including pain, deafness, and cardiac and kidney dysfunction.

3 Sep 2010

Egg recall raises questions about FDA

The recent salmonella outbreak/egg recall is raising questions about whether the FDA is fulfilling its regulatory role, PBS' NewsHour reports. "For the past few years, it's been one food safety scare after another. There was E. coli-laced spinach, salmonella-tainted peppers. ... There have also been problems with drugs. The ingredients in a contaminated blood thinner came from China.

3 Sep 2010

Vaccine News and Research

Latest Vaccine News and Research

Emergent BioSolutions receives early termination grant to acquire Trubion

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic

AVAC welcomes new Global HIV Vaccine Enterprise Scientific Strategic Plan

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

Risks of 'imported' measles

New vaccines fact sheet released by Research!America

Personalized reminders effective in encouraging seniors to get annual flu shots

K-State University receives patent for procedures to source stem cells from umbilical cord

Fluctuation in PCV-7 vaccine dosing time increases pneumococcal serotype 19A strains: Study

CDC ramps up production of new three-in-one flu vaccine

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

VOA News examines U.S. Global Health Initiative

AVAC calls for economic and political support for CAPRISA 004 microbicide trial's critical follow-up studies

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

Regional Director of WHO Africa warns of impact global financial situation will have on health systems, MDGs

Research on immune system can develop new therapy for inflammation, tumors

BARDA awards contract to develop treatment for ionizing radiation exposure

Researchers identify two proteins in cellular response to mechanical stimulation

Egg recall raises questions about FDA

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in